Company / Operating Income
Arcadia Biosciences, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$3.6M
FY2025
5-year range
-$35.5M / -$3.6M
FY2021-FY2025
Trend
+40.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has increased for 3 consecutive years, from -$36M in FY2022 to -$4M in FY2025.
Based on SEC 10-K filings.
-$4M in FY2025.
Improved from -$14M to -$4M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Arcadia Biosciences, Inc.'s operating income has grown for 3 consecutive years.
- In FY2025, operating income increased 40.2% year-over-year.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.6M | +40.2% |
| FY2024 | -$6.1M | +56.4% |
| FY2023 | -$14.0M | +60.6% |
| FY2022 | -$35.5M | -178.0% |
| FY2021 | -$12.8M | +34.1% |
| FY2020 | -$19.4M | -14.9% |
| FY2019 | -$16.9M | -17.8% |
| FY2018 | -$14.3M | +23.1% |
| FY2017 | -$18.6M | -19.6% |
| FY2016 | -$15.6M | -2.7% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026